Radiopharm Theranostics (ADR) (RADX)
Develops targeted radiopharmaceutical diagnostics and therapies for solid tumors.
Something off on this page? Send us feedback.
Develops targeted radiopharmaceutical diagnostics and therapies for solid tumors, with clinical programs spanning brain-metastasis and pancreatic-cancer imaging alongside radionuclide treatments. It is pre-commercial, earning development revenue from Lantheus work while relying on external licenses, manufacturers, isotope suppliers, clinical sites, and partners.
Builds molecular targeting agents into imaging diagnostics and radionuclide therapies for solid tumors. The clinical portfolio includes RAD101 for imaging suspected recurrent brain metastases and RAD301 for pancreatic-cancer imaging, plus RAD202, RAD204, RV-01, and RAD402 therapeutic programs targeting HER2, PD-L1, B7-H3, or KLK3/PSA.
Works from Carlton, Australia with a small internal R&D team and a development footprint spanning the United States and Australia. No candidate has been approved for sale; revenue has come from Lantheus-funded development work rather than products. Much of the portfolio is licensed or developed through partners, and execution depends on clinical trials, regulatory clearance, third-party manufacturing, therapeutic-isotope supply, and partner relationships.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.0M · Total debt $0 · Total assets $43.2M · Shareholders' equity $17.7M
- Revenue
- $1.0M
- Operating income
- −$28.7M
- Net income
- −$20.5M
Reported in AUD, converted at the latest exchange rate
No dividends on record.
| Institutions7 holders · as of Mar 31, 2026 | 3,982.92% | 51.31M ADS | |
| Adds to | 3,982.92% |
1.29M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
These groups come from separate filings that can overlap, so they add to 3,982.92%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Stonepine Capital Management, LLCInstitution | 3,959.01% | 51.00M ADS | 13Fas of Mar 31, 2026 |
Silverarc Capital Management, LLCInstitution | 14.55% | 187,406 ADS | 13Fas of Mar 31, 2026 |
HSBC Holdings PLCInstitution | 4.76% | 61,372 ADS | 13Fas of Mar 31, 2026 |
Regal Partners LtdInstitution | 3.12% | 40,138 ADS | 13Fas of Mar 31, 2026 |
PNC Financial Services Group, Inc.Institution | 1.24% | 16,000 ADS | 13Fas of Mar 31, 2026 |
| See all 13 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Novartis (ADR)
Commercial prostate RLT and scaled radioligand infrastructure.
- Telix Pharmaceuticals
Brain-tumor PET imaging and broad oncology radiopharmaceuticals.
- Perspective Therapeutics
Early-stage solid-tumor theranostics and alpha-particle therapy.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Radiopharm Theranostics (ADR) | $2.13 | −6.17% | $2.8M | — | — | 7.7 | — |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Telix Pharmaceuticals | $11.75 | +2.62% | $3.88B | 114.7 | — | 4.2 | +22.8% |
| Perspective Therapeutics | $3.11 | +0.32% | $353.5M | — | — | 966.0 | −72.1% |
| Median | 69.6 | 17.3 | 5.6 | +0.9% |